Overview

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status:
Completed

Trial end date:
2020-06-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin